TELOTRISTAT ETIPRATE THERAPY

Telotristat ethyl is indicated for the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone.

This medication is designed to reduce the production of serotonin which can be measured by u5-HIAA.

Telotristat (Xermelo)

For the treatment of refractory carcinoid syndrome diarrhea, in combination with somatostatin analogue (SSA) therapy, in patients inadequately controlled by SSA therapy alone.

250mg tablets three times daily

Not funded

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for theTreatment of Carcinoid Syndrome

Telotristat Etiprate Therapy – XERMELO – PRODUCT MONOGRAPH